将接触素-1 鉴定为神经母细胞瘤的潜在生物标记物和治疗靶点

IF 3.9 3区 工程技术 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Christa N Grant, Carson A Wills, Xiaoming Liu, Longgui Chen, Zhenqiu Liu, Hong-Gang Wang
{"title":"将接触素-1 鉴定为神经母细胞瘤的潜在生物标记物和治疗靶点","authors":"Christa N Grant, Carson A Wills, Xiaoming Liu, Longgui Chen, Zhenqiu Liu, Hong-Gang Wang","doi":"10.3390/biomedicines12112606","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Neuroblastoma is a common pediatric solid tumor with poor outcomes in high-risk patients. The identification of new therapeutic biomarkers is critical for the treatment of disease.</p><p><strong>Methods: </strong>An analysis of large publicly available datasets of tumor gene expression was performed. In vivo studies were performed to elucidate the role of contactin-1 (CNTN1) in tumor progression.</p><p><strong>Results: </strong>Expression of the glycoprotein CNTN1 is elevated in neuroblastoma compared to other tumor types. CNTN1 expression is higher in stage 1 and non-MYCN-amplified tumors, compared to more aggressive stage 4 and MYCN-amplified tumors. Moreover, high CNTN1 expression is associated with increased overall survival in neuroblastoma patients. In vivo studies demonstrate reduced metastasis in mice xenografted with CNTN1 knockout tumors compared to wildtype.</p><p><strong>Conclusions: </strong>The results of this study suggest that CNTN1 is a potential biomarker and therapeutic target in neuroblastoma. Further investigation of CNTN1 could have significant clinical implications for improving neuroblastoma treatment.</p>","PeriodicalId":8937,"journal":{"name":"Biomedicines","volume":"12 11","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11591853/pdf/","citationCount":"0","resultStr":"{\"title\":\"Identification of Contactin-1 as a Potential Biomarker and Therapeutic Target in Neuroblastoma.\",\"authors\":\"Christa N Grant, Carson A Wills, Xiaoming Liu, Longgui Chen, Zhenqiu Liu, Hong-Gang Wang\",\"doi\":\"10.3390/biomedicines12112606\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Neuroblastoma is a common pediatric solid tumor with poor outcomes in high-risk patients. The identification of new therapeutic biomarkers is critical for the treatment of disease.</p><p><strong>Methods: </strong>An analysis of large publicly available datasets of tumor gene expression was performed. In vivo studies were performed to elucidate the role of contactin-1 (CNTN1) in tumor progression.</p><p><strong>Results: </strong>Expression of the glycoprotein CNTN1 is elevated in neuroblastoma compared to other tumor types. CNTN1 expression is higher in stage 1 and non-MYCN-amplified tumors, compared to more aggressive stage 4 and MYCN-amplified tumors. Moreover, high CNTN1 expression is associated with increased overall survival in neuroblastoma patients. In vivo studies demonstrate reduced metastasis in mice xenografted with CNTN1 knockout tumors compared to wildtype.</p><p><strong>Conclusions: </strong>The results of this study suggest that CNTN1 is a potential biomarker and therapeutic target in neuroblastoma. Further investigation of CNTN1 could have significant clinical implications for improving neuroblastoma treatment.</p>\",\"PeriodicalId\":8937,\"journal\":{\"name\":\"Biomedicines\",\"volume\":\"12 11\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11591853/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedicines\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3390/biomedicines12112606\",\"RegionNum\":3,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicines","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/biomedicines12112606","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:神经母细胞瘤是一种常见的儿科实体瘤,高危患者的预后较差。确定新的治疗生物标志物对疾病的治疗至关重要:方法:对可公开获得的大型肿瘤基因表达数据集进行了分析。方法:对可公开获得的大型肿瘤基因表达数据集进行了分析,并进行了体内研究,以阐明接触素-1(CNTN1)在肿瘤进展中的作用:结果:与其他肿瘤类型相比,神经母细胞瘤中糖蛋白 CNTN1 的表达升高。与侵袭性更强的4期和MYCN扩增肿瘤相比,CNTN1在1期和非MYCN扩增肿瘤中的表达更高。此外,CNTN1 的高表达与神经母细胞瘤患者总生存率的提高有关。体内研究表明,与野生型肿瘤相比,CNTN1基因敲除肿瘤异种移植小鼠的转移率降低:本研究结果表明,CNTN1 是神经母细胞瘤的潜在生物标志物和治疗靶点。对 CNTN1 的进一步研究可能对改善神经母细胞瘤的治疗具有重要的临床意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Identification of Contactin-1 as a Potential Biomarker and Therapeutic Target in Neuroblastoma.

Background: Neuroblastoma is a common pediatric solid tumor with poor outcomes in high-risk patients. The identification of new therapeutic biomarkers is critical for the treatment of disease.

Methods: An analysis of large publicly available datasets of tumor gene expression was performed. In vivo studies were performed to elucidate the role of contactin-1 (CNTN1) in tumor progression.

Results: Expression of the glycoprotein CNTN1 is elevated in neuroblastoma compared to other tumor types. CNTN1 expression is higher in stage 1 and non-MYCN-amplified tumors, compared to more aggressive stage 4 and MYCN-amplified tumors. Moreover, high CNTN1 expression is associated with increased overall survival in neuroblastoma patients. In vivo studies demonstrate reduced metastasis in mice xenografted with CNTN1 knockout tumors compared to wildtype.

Conclusions: The results of this study suggest that CNTN1 is a potential biomarker and therapeutic target in neuroblastoma. Further investigation of CNTN1 could have significant clinical implications for improving neuroblastoma treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biomedicines
Biomedicines Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
5.20
自引率
8.50%
发文量
2823
审稿时长
8 weeks
期刊介绍: Biomedicines (ISSN 2227-9059; CODEN: BIOMID) is an international, scientific, open access journal on biomedicines published quarterly online by MDPI.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信